Edward Aloysius Sullivan Jr. - Jan 4, 2023 Form 4/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
Jan 4, 2023
Transactions value $
$16,249
Form type
4/A - Amendment
Date filed
2/14/2023, 04:31 PM
Date Of Original Report
Jan 6, 2023
Previous filing
Feb 14, 2023
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMRA Common Stock Purchase $13.5K +11K +126.4% $1.23 19.7K Jan 4, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Warrant (Right to Buy) Purchase $2.74K +11K $0.25 11K Jan 4, 2023 Common Stock 22K $1.23 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4/A is being filed to (i) correct a typographical error in the transaction code disclosed in Column 3 in Table I and Column 4 in Table II in the original Form 4, filed on January 6, 2023, from "A" to "P" and (ii) correct a typographical error in the power-of-attorney of the reporting person.
F2 The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 10,979 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
F3 The exercisability of the Warrants is subject to a 9.99% beneficial ownership limitation.

Remarks:

Exhibit 24 Power of Attorney filed herewith.